177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial

Authors: Michael J. Morris, Daniel Castellano, Ken Herrmann, Johann S. de Bono, Neal D. Shore, Kim N., Michael J. Crosby, Josep M. Piulats, Aude Fléchon, Xiao X. Wei, Hakim Mahammedi, Guilhem Roubaud, Hana Študentová, James Nagarajah, Begoña Mellado, Álvaro Montesa-Pino, Euloge Kpamegan, Samson Ghebremariam, Teri Kreisl, Celine Wilke, Katja Lehnhoff, Oliver Sartor, Karim Fizazi - The Lancet 2024 cited by 258